CARA Cara Therapeutics Inc

Price (delayed)

$14.55

Market cap

$728.26M

P/E Ratio

44.09

Dividend/share

N/A

EPS

$0.33

Enterprise value

$710.22M

Highlights
The quick ratio has surged by 183% year-on-year and by 7% since the previous quarter
Cara Therapeutics's EPS has soared by 113% YoY and by 83% from the previous quarter
Cara Therapeutics's equity has increased by 44% YoY but it has decreased by 7% from the previous quarter
CARA's debt is up by 20% year-on-year but it is down by 7% since the previous quarter
CARA's gross profit is down by 4.6% from the previous quarter
The revenue has declined by 4.6% since the previous quarter

Key stats

What are the main financial stats of CARA
Market
Shares outstanding
50.05M
Market cap
$728.26M
Enterprise value
$710.22M
Valuations
Price to earnings (P/E)
44.09
Price to book (P/B)
3.15
Price to sales (P/S)
5.63
EV/EBIT
52.76
EV/EBITDA
48.49
EV/Sales
5.51
Earnings
Revenue
$128.92M
EBIT
$13.46M
EBITDA
$14.65M
Free cash flow
$8.82M
Per share
EPS
$0.33
Free cash flow per share
$0.18
Book value per share
$4.62
Revenue per share
$2.58
TBVPS
$5.01
Balance sheet
Total assets
$250.23M
Total liabilities
$19.77M
Debt
$4.89M
Equity
$230.46M
Working capital
$171.83M
Liquidity
Debt to equity
0.02
Current ratio
11.4
Quick ratio
10.55
Net debt/EBITDA
-1.23
Margins
EBITDA margin
11.4%
Gross margin
100%
Net margin
10.9%
Operating margin
9.2%
Efficiency
Return on assets
6.7%
Return on equity
7.5%
Return on invested capital
9.1%
Return on capital employed
5.8%
Return on sales
10.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CARA stock price

How has the Cara Therapeutics stock price performed over time
Intraday
-0.68%
1 week
4.23%
1 month
8.99%
1 year
-10.13%
YTD
-3.83%
QTD
-32.98%

Financial performance

How have Cara Therapeutics's revenue and profit performed over time
Revenue
$128.92M
Gross profit
$128.92M
Operating income
$11.83M
Net income
$14.03M
Gross margin
100%
Net margin
10.9%
Cara Therapeutics's operating margin has soared by 130% from the previous quarter and by 102% YoY
Cara Therapeutics's operating income has soared by 120% from the previous quarter and by 110% YoY
CARA's net income has soared by 112% YoY and by 67% QoQ
CARA's net margin has surged by 102% year-on-year and by 76% since the previous quarter

Growth

What is Cara Therapeutics's growth rate over time

Valuation

What is Cara Therapeutics stock price valuation
P/E
44.09
P/B
3.15
P/S
5.63
EV/EBIT
52.76
EV/EBITDA
48.49
EV/Sales
5.51
Cara Therapeutics's EPS has soared by 113% YoY and by 83% from the previous quarter
Cara Therapeutics's equity has increased by 44% YoY but it has decreased by 7% from the previous quarter
The P/B is 43% lower than the 5-year quarterly average of 5.5 and 30% lower than the last 4 quarters average of 4.5
CARA's P/S is 99% below its 5-year quarterly average of 433.4 and 67% below its last 4 quarters average of 17.2
The revenue has declined by 4.6% since the previous quarter

Efficiency

How efficient is Cara Therapeutics business performance
CARA's ROA has soared by 112% YoY and by 56% QoQ
CARA's return on invested capital has surged by 112% year-on-year and by 54% since the previous quarter
Cara Therapeutics's return on equity has surged by 111% YoY and by 50% QoQ
Cara Therapeutics's ROS has soared by 102% YoY and by 82% from the previous quarter

Dividends

What is CARA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CARA.

Financial health

How did Cara Therapeutics financials performed over time
The quick ratio has surged by 183% year-on-year and by 7% since the previous quarter
Cara Therapeutics's current ratio has soared by 180% YoY and by 8% from the previous quarter
CARA's debt is 98% smaller than its equity
Cara Therapeutics's equity has increased by 44% YoY but it has decreased by 7% from the previous quarter
The company's debt to equity fell by 33% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.